RCKT at a glance
ROCKET PHARMACEUTICALS, INC. (RCKT, SEC CIK 1281895) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ROCKET PHARMACEUTICALS, INC. (RCKT) reported revenue of $0 and a net loss of $223.1 million. Diluted EPS was -$2.01.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding ROCKET PHARMACEUTICALS, INC. (RCKT) shares worth $110.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Wilson Martin on November 18, 2026 of 677 shares at $2.18 per share.
- In the last 90 days, RCKT insiders reported 0 open-market purchases ($0) and 7 open-market sales ($418K) on Form 4, a net sale of $418K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$418K
- 13F holders
- 28 funds
- $110.6M · −2 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New secured debt risk: September 30, 2026 Loan Agreement provides up to $150.0 million, secured by substantially all assets
- Regulatory and covenant risk: RP-A501 clinical hold or discontinuation raises qualified-cash requirement to 75% of outstanding principal
- Operational flexibility risk: Loan covenants restrict financing, acquisitions, asset licensing, and strategic transactions
- Interest-rate risk: Term Loans bear floating interest at the greater of 9.15% or prime rate plus 2.40%
- Liquidity risk: $50.0 million final tranche requires lenders’ investment committee approval in its sole discretion
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales; KRESLADI™ not expected to generate near-term material revenue
- Operating loss $51.0M vs $52.2M YoY; operating margin not applicable with zero revenue
- Danon R&D $6.2M vs $5.6M YoY, strongest program investment; RP-A601 R&D $1.0M vs $1.5M
- Cash, equivalents and investments $279.4M at September 30; operating cash use $124.1M nine-month
- Hercules financing provided $35M initial draw; runway projected into third quarter 2028, with additional borrowing potentially extending to 2029
AI summary of the RCKT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial information announced for quarter ended September 30, 2026
- Investor focus: Exhibit 99.1 contains the company’s detailed results and management commentary
Item EX-99.1: Item EX-99.1
- FDA alignment supports a 12-patient RP-A501 pivotal Phase 2, with dosing targeted by mid-2027 and topline results in mid-2028
- Danon efficacy bar: at least 7 of 12 patients meeting both LAMP2 expression and 10% LV mass-index reduction endpoints
Item EX-99.1: Item EX-99.1
- Credit facility up to $150 million with Hercules Capital, adding funding flexibility for RP-A501’s pivotal Phase 2 Danon study
- $35 million funded at closing, with potential additional draws of $35 million, $30 million upon a Danon milestone, and $50 million subject to approval
Item EX-99.2: Item EX-99.2
- RP-A501 Phase 1 showed durable cardiac benefit up to 7 years, with 100% overall survival and transplant-free survival median not reached
- Pivotal Phase 2 Cohort 4 uses recalibrated dose and revised immunomodulation after serious adverse events in discontinued Cohort 3
Item 1.01: Entry into a Material Definitive Agreement
- $35.0M funded, with total senior secured borrowing capacity up to $150.0M across five tranches
- Floating interest rate: greater of prime rate or 6.75%, plus 2.40%, creating substantial rate exposure
Item 7.01: Regulation FD Disclosure
- Loan Agreement with Hercules announced, indicating new financing for Rocket Pharmaceuticals
- Investor presentation updates the Danon Disease Program, relevant to clinical and corporate outlook
Item 3.02: Unregistered Sales of Equity Securities
- Warrants issued to lenders in a private placement under Securities Act Section 4(a)(2)
- Underlying common shares unregistered, creating potential future dilution if warrants are exercised
Item 7.01: Regulation FD Disclosure
- FDA alignment supports continued enrollment and dosing in RP-A501’s global pivotal Phase 2 Danon disease trial
- Recalibrated dose and 12-patient pivotal population define the updated trial design
Item EX-99.1: Item EX-99.1
- FDA alignment preserves RP-A501’s pivotal Phase 2 path and potential accelerated approval strategy in Danon disease
- Pivotal population set at 12 male patients receiving 3.8 × 10¹³ GC/kg; first three patients count toward efficacy population
AI summaries of RCKT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RCKT
Don't miss the next RCKT filing
- Alerts as it files. A push when RCKT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RCKT, by share count.
- Ask anything. An AI agent that reads every RCKT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Wilson Martin | Sell | Nov 18, 2026 | 677 | $2.18 |
| Shah Gaurav | Sell | Nov 18, 2026 | 2,216 | $2.18 |
| Wilson Martin | Sell | Nov 13, 2026 | 4,087 | $2.25 |
| Shah Gaurav | Sell | Nov 13, 2026 | 3,020 | $2.25 |
| Chaudhuri Sarbani | Sell | Nov 9, 2026 | 4,872 | $2.33 |
| Wilson Martin | Sell | Nov 5, 2026 | 53,389 | $2.39 |
| Wilson Martin | Sell | Sep 11, 2026 | 75,364 | $3.40 |
| Shah Gaurav | Sell | Aug 18, 2026 | 2,293 | $3.38 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $0 |
| Operating Income | - | -$273.2M | -$231.7M |
| Net Income | -$245.6M | -$258.7M | -$223.1M |
| Balance Sheet | |||
| Total Assets | $566.3M | $527.7M | $330.4M |
| Equity | - | $463.2M | $277.2M |
| ROE | - | -55.9% | -80.5% |
| Per Share | |||
| EPS | $-2.92 | $-2.73 | $-2.01 |
| Cash Flow | |||
| Operating CF | - | -$209.7M | -$190.0M |
| CapEx | $16.4M | $5.9M | $440K |
Source: XBRL data in ROCKET PHARMACEUTICALS, INC. (RCKT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RCKT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $110.6M |
| Q2 2026 | 30 | $157.7M |
| Q1 2026 | 29 | $158.5M |
| Q4 2025 | 26 | $149.2M |
| Q3 2025 | 27 | $126.9M |
| Q2 2025 | 26 | $78.1M |
| Q1 2025 | 23 | $139.0M |
| Q4 2024 | 19 | $223.8M |
- BlackRock+3.24M (+33%)
- Millennium Management+820.5K (+21%)
- Morgan Stanley+434.5K (+41%)
- Citadel Advisors LLC+294.5K (+414%)
- Dimensional Fund Advisors+220.6K (+20%)
- Vanguard Portfolio Management LLC−4.38M (-75%)
- AQR Capital Management−1.71M (-51%)
- JPMorgan Chase & Co−1.22M (-62%)
- Goldman Sachs Group−1.00M (-35%)
- Citigroup−256.3K (-5%)
- M&T Bank+21.1K
- FMR LLC (Fidelity)−488.3K
- Marex Group plc−72.5K
- Franklin Resources−10.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 208 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RCKT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| 4 | Sep 15, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 8-K | Aug 27, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 4 | Jul 6, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RCKT SEC filings: frequently asked questions
Are RCKT insiders buying or selling?
In the last 90 days, ROCKET PHARMACEUTICALS, INC. (RCKT) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $417,906 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RCKT stock?
As of September 30, 2026, the largest ROCKET PHARMACEUTICALS, INC. (RCKT) holders among the 13F filers tracked by SignalX were BlackRock ($34.6 million), Millennium Management ($12.7 million), Citigroup ($12.1 million), Vanguard Capital Management LLC ($10.1 million), State Street Corp ($4.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RCKT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ROCKET PHARMACEUTICALS, INC. (RCKT) reported revenue of $0 and a net loss of $223.1 million. Diluted EPS was -$2.01. The figures come from the XBRL data in the 10-K.
What did RCKT report in its latest 8-K?
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial information announced for quarter ended September 30, 2026.
What are the latest RCKT SEC filings?
ROCKET PHARMACEUTICALS, INC. (RCKT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 20, 2026.
What is RCKT's SEC CIK number?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s SEC Central Index Key (CIK) is 1281895. EDGAR lists every RCKT filing under that number.
Ask anything about RCKT
The research agent reads RCKT's filings, financials, insider trades and 13F holders, then answers with sources.